Aug 2026· Frontiers in Pharmacology· Vol 17· 0 citations· 130 references
Medicine
TL;DR
This review systematically summarizes the major mechanisms underlying ADC resistance in BC and outlines potential strategies to overcome it, including the development of next-generation ADCs, combination therapies, and predictive biomarkers.
Abstract
Antibody-drug conjugates (ADCs) have made important advances in the treatment of bladder cancer (BC) in recent years and have demonstrated significant clinical benefit in locally advanced or metastatic urothelial carcinoma (UC). However, the emergence of resistance remains a key factor limiting the durability of their therapeutic efficacy. Current evidence indicates that resistance to ADCs in BC is a complex process driven by multiple tumor-intrinsic and tumor-extrinsic factors. This review systematically summarizes the major mechanisms underlying ADC resistance in BC and outlines potential strategies to overcome it, including the development of next-generation ADCs, combination therapies, and predictive biomarkers. A deeper understanding of BC-specific mechanisms of ADC resistance will help promote the development of more precise and individualized ADC-based treatment strategies.
The rationale for targeting established and emerging antigens in non-small cell and small cell lung cancer, including HER2, TROP2, c-MET, HER3, CEACAM5, DLL3, and other promising targets currently under clinical investigation are discussed.
P. Paliogiannis, G. Fara, A. Zinellu et al.· Current Issues in Molecular...· 0 citations
Simple Summary 1. Treatment outcomes for urothelial carcinoma have significantly improved recently due to advancements in antibody-based therapies, particularly immune checkpoint inhibitors (ICIs) and antibody-drug conjugates (ADCs). 2. ICIs enhance the patient’s immune response against cancer cells, whereas ADCs selec...
S. Go, Viozzy Florendinha da Costa Xavier, M. Kang et al.· Cancers· 0 citations
Next-generation ADCs may function not only as targeted cytotoxic agents but also as modulators of antitumor immunity in gastric cancer, and integrating tumor-antigen biology with immune-contextual features may enable more rational patient selection and therapeutic combinations.
Hong-Hua Su, Chun-Yin Yang, Jia-Yun Ge· Frontiers in Immunology· 0 citations
Esophageal cancer remains one of the most lethal malignancies worldwide, with particularly poor outcomes following disease progression after first-line chemoimmunotherapy. Antibody-drug conjugates (ADCs) have emerged as a transformative therapeutic class that combines the targeting precision of monoclonal antibodies wi...
Da-Peng Wu, Wei Chen, Qi Zhao et al.· Current Treatment Options in...· 0 citations
This article systematically elaborates the synergistic biological mechanisms by which targeted drugs induce immunogenic cell death, re-adjust the tumor immune microenvironment, and immune checkpoint inhibitors amplify and prolong the therapeutic effect and thoroughly examines the challenges that may arise from combined...
Zong-Hua Wang· International Journal of Bio...· 0 citations
Antibody-drug conjugates (ADCs) have transformed the treatment landscape of breast cancer and redefined the conceptual distinction between targeted therapy and conventional chemotherapy. Originally conceived as “magic bullets” that selectively deliver cytotoxic warheads to antigen-expressing tumor cells, clinical and m...
Chen-Xu Guo, L. Ellisen· Journal of Clinical Investig...· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.
